Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 31 May 2021, 17:54 HKT/SGT
Share:
    

Source: Eisai
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

TOKYO, May 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society.

Through this alliance, Eisai and ITO EN aim to contribute to the solution of dementia, which is one of the important social issues, with integrating Eisai's wealth of experience and knowledge in drug creation and disease awareness activities in the area of dementia, as well as Eisai's solution measures such as digital technology, and ITO EN's customer network through its community-based sales activities, as well as ITO EN's problem-solving project related to cognitive function based on abundant research on Matcha (powdered green tea). The specific initiatives planned are as follows.

1. Providing the packaged solution
As support for holding seminars on exercise and food related to dementia disease awareness and brain health by local governments for residents, the packaged solution plans to be provided through ITO EN's 186 business offices nationwide. The packaged solution includes Eisai's information materials for disease awareness, opportunities for checking brain performance using Eisai's brain performance (brain-health) self-check tool "NouKNOWTM" (pronounced "NOH-NOH", non-medical equipment), and ITO EN's information and services related to Matcha and health.

2. Providing a set of products focusing on brain health
A set product which includes the Foods with Function Claims "Oi Ocha OMATCHA POWDER (stick 1.7g x 32)" produced by ITO EN, a prepaid card that can be used for "NouKNOW" and Eisai's information materials related to brain health will be distributed in Japan.

3. Providing an opportunity to check brain performance at events and campaigns hosted by ITO EN
At the events and campaigns hosted by ITO EN, participants will be provided with the information on brain health and the opportunity to check brain performance using "NouKNOW".

4. Initiation of brain performance check trial internally at ITO EN, towards the future utilization of brain performance checks in corporate health examinations
As a trial for the utilization of "NouKNOW" in corporate health examinations, verification of the effects of health consciousness and behavioral changes based on regular brain performance checks among willing ITO EN employees has been ongoing.

Eisai, which aims to eliminate the diverse anxieties of each individual (The People) by constructing a dementia ecosystem through coexisting with other industries and organizations, and ITO EN, which explores the potential of tea and aims to be a health creation company that contributes to the era of 100 years of life, will promote co-creation of value toward the realization of a healthy and long-lived society so that people can lead a happy life in their own way by combining the strengths of both company.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 18, 2024 09:53 HKT/SGT
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 17, 2024 15:17 HKT/SGT
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 3, 2024 15:24 HKT/SGT
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 1, 2024 08:39 HKT/SGT
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Mar 29, 2024 14:51 HKT/SGT
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 14:19 HKT/SGT
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 13:32 HKT/SGT
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 21, 2024 16:36 HKT/SGT
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 15:10 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 6, 2024 16:47 HKT/SGT
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: